Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.47 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 3/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394140 | 0.84 | AXL (0.60) | GAACSNK1A1CSNK1DCSNK1ECSNK1G2 | |
| SCHEMBL619424 | 0.84 | GAA (0.59) | GAACSNK1A1CSNK1DCSNK1ECSNK1G2 | |
| SCHEMBL31339925 | 0.84 | GAA (0.59) | GAACSNK1A1CSNK1DCSNK1ECSNK1G2 | |
| SCHEMBL289038 | 0.84 | GAA (0.43) | GAACSNK1A1CSNK1DCSNK1ECSNK1G2 | |
| SCHEMBL17041315 | 0.84 | GAA (0.43) | GAACSNK1A1CSNK1DCSNK1ECSNK1G2 | |
| SCHEMBL289039 | 0.84 | GAA (0.43) | GAACSNK1A1CSNK1DCSNK1ECSNK1G2 | |
| SCHEMBL1261588 | 0.84 | AXL (0.60) | GAACSNK1A1CSNK1DCSNK1ECSNK1G2 | |
| SCHEMBL18103466 | 0.84 | GAA (0.43) | GAACSNK1A1CSNK1DCSNK1ECSNK1G2 | |
| SCHEMBL17558948 | 0.84 | AXL (0.55) | GAACSNK1A1CSNK1DCSNK1ECSNK1G2 | |
| SCHEMBL28892378 | 0.81 | CSNK1A1 (0.43) | GAACSNK1A1CSNK1DCSNK1ECSNK1G2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2020132045-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEUROPROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020081923-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8088883-B2 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-2172470-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | SARM1, NNMT, NQO1 | GAA 402/4885CSNK1A1 2482/4885CSNK1D 3570/4885 |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | GAA 4362/4885CSNK1A1 4242/4885CSNK1D 4619/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | GAA 4519/4885CSNK1A1 4000/4885CSNK1D 4316/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | GAA 1326/4885CSNK1A1 1766/4885CSNK1D 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.